Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/allo-hsct-shows-long-term-benefit-hepatosplenic-lymphoma-2026a1000xdx?src= At 3 years, more than half of patients with hepatosplenic T-cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation (HSCT) were alive, according to a retrospective study. Lactate dehydrogenase at or below the upper limit of normal at diagnosis and complete remission before transplantation were both associated with significantly better survival outcomes. In patients receiving autologous transplantation, relapse occurred in 50% by 3 years, despite the majority being in complete remission at...